UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties

Journal of medicinal chemistry, 2011-09, Vol.54 (17), p.6014-6027

2011

Volltextzugriff (PDF)

BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy

Molecular cancer therapeutics, 2010-06, Vol.9 (6), p.1562-1573

2010

Volltextzugriff (PDF)

Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)

Cancer chemotherapy and pharmacology, 2019-01, Vol.83 (1), p.97-105

2019

Volltextzugriff (PDF)

The Combination of Metformin and Valproic Acid Has a Greater Anti-tumoral Effect on Prostate Cancer Growth In Vivo than Either Drug Alone

In vivo (Athens), 2019-01, Vol.33 (1), p.99-108

2019

Volltextzugriff (PDF)

The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer

Cancer biology & therapy, 2014-01, Vol.15 (11), p.1552-1560

2014

Volltextzugriff (PDF)

Effects of the insecticide amitraz, an α2-adrenergic receptor agonist, on human luteinized granulosa cells

Human reproduction (Oxford), 2005-11, Vol.20 (11), p.3018-3025

2005

Volltextzugriff (PDF)

Abstract 4695: Targeting the LGR5 complex with BNC101 to improve checkpoint inhibitor therapy in colorectal cancer

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4695-4695

2017

Volltextzugriff (PDF)

Evidence for ovarian granulosa stem cells: telomerase activity and localization of the telomerase ribonucleic acid component in bovine ovarian follicles

Biology of reproduction, 1999-08, Vol.61 (2), p.358-366

1999

Volltextzugriff (PDF)

Discovery and validation of drug targets for tumour angiogenesis

Expert opinion on therapeutic targets, 2005-04, Vol.9 (2), p.211-215

2005

Volltextzugriff (PDF)

Abstract 4982: BNC105 induces tumor micro-environment changes which enhance the efficacy of checkpoint inhibitor therapy in preclinical models

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4982-4982

2016

Volltextzugriff (PDF)

Abstract 3910: Characterization of BNC101 a human specific monoclonal antibody targeting the GPCR LGR5: First-in-human evidence of target engagement

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3910-3910

2018

Volltextzugriff (PDF)

Abstract 1881: The microtubule-disrupting drug BNC105 is a potent inducer of apoptosis in AML patient samples

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1881-1881

2018

Volltextzugriff (PDF)

Abstract B92: The tubulin-targeting agent BNC105 potentiates the efficacy of immune checkpoint inhibitors in preclinical models of colorectal cancer

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B92-B92

2015

Volltextzugriff (PDF)

Abstract B174: Complementary activity of the vascular disruption agent BNC105 and the hypoxia-activated prodrug evofosfamide (TH-302) in suppressing the growth of preclinical renal and breast solid tumors

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B174-B174

2015

Volltextzugriff (PDF)

Abstract B67: Induction of tumor hypoxia synergises with inhibitors of tumor metabolic and angiogenic adaptive responses to suppress tumor growth and enhance host survival

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.B67-B67

2013

Volltextzugriff (PDF)

Abstract 4039: Harnessing the tumor adaptive response to hypoxia to identify novel combinations of the vascular disrupting agent BNC105 with targeted therapeutics

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4039-4039

2013

Volltextzugriff (PDF)

Abstract 2774: Anti-cancer activity of the tumor-selective, hypoxia-inducing, agent BNC105 in platinum resistant ovarian cancer

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2774-2774

2012

Volltextzugriff (PDF)

Abstract 3543: Anti-tumor activity of the vascular disruption agent BNC105 in models of mesothelioma and lung cancer

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3543-3543

2011

Volltextzugriff (PDF)

Abstract 662: Evaluation of the anti-cancer effects of the tumor selective vascular disruption agent BNC105 in preclinical renal cancer models

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.662-662

2011

Volltextzugriff (PDF)

A phase I study of the vascular-disrupting agent BNC105P in combination with gemcitabine-carboplatin in platinum-sensitive ovarian cancer patients in first or second relapse

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.5524-5524

2014

Volltextzugriff (PDF)

A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients: Updated phase I results of the Disruptor-1 trial

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.4563-4563

2013

Volltextzugriff (PDF)

Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2013-02, Vol.31 (6_suppl), p.397-397

2013

Volltextzugriff (PDF)

Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzobfuran (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties

Journal of medicinal chemistry, 2011-09, Vol.54 (17), p.6014

2011

Volltextzugriff (PDF)

Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.4603-4603

2012

Volltextzugriff (PDF)

Phase II trial of BNC105P as second-line chemotherapy for advanced malignant pleural mesothelioma (MPM): Australasian Lung Cancer Trials Group and NHMRC Clinical Trials Centre Collaboration

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7079-7079

2012

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)
Japanisch
(1)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties

BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy

Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)

The Combination of Metformin and Valproic Acid Has a Greater Anti-tumoral Effect on Prostate Cancer Growth In Vivo than Either Drug Alone

The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer

Effects of the insecticide amitraz, an α2-adrenergic receptor agonist, on human luteinized granulosa cells

Abstract 4695: Targeting the LGR5 complex with BNC101 to improve checkpoint inhibitor therapy in colorectal cancer

Evidence for ovarian granulosa stem cells: telomerase activity and localization of the telomerase ribonucleic acid component in bovine ovarian follicles

Discovery and validation of drug targets for tumour angiogenesis

Abstract 4982: BNC105 induces tumor micro-environment changes which enhance the efficacy of checkpoint inhibitor therapy in preclinical models

Abstract 3910: Characterization of BNC101 a human specific monoclonal antibody targeting the GPCR LGR5: First-in-human evidence of target engagement

Abstract 1881: The microtubule-disrupting drug BNC105 is a potent inducer of apoptosis in AML patient samples

Abstract B92: The tubulin-targeting agent BNC105 potentiates the efficacy of immune checkpoint inhibitors in preclinical models of colorectal cancer

Abstract B174: Complementary activity of the vascular disruption agent BNC105 and the hypoxia-activated prodrug evofosfamide (TH-302) in suppressing the growth of preclinical renal and breast solid tumors

Abstract B67: Induction of tumor hypoxia synergises with inhibitors of tumor metabolic and angiogenic adaptive responses to suppress tumor growth and enhance host survival

Abstract 4039: Harnessing the tumor adaptive response to hypoxia to identify novel combinations of the vascular disrupting agent BNC105 with targeted therapeutics

Abstract 2774: Anti-cancer activity of the tumor-selective, hypoxia-inducing, agent BNC105 in platinum resistant ovarian cancer

Abstract 3543: Anti-tumor activity of the vascular disruption agent BNC105 in models of mesothelioma and lung cancer

Abstract 662: Evaluation of the anti-cancer effects of the tumor selective vascular disruption agent BNC105 in preclinical renal cancer models

A phase I study of the vascular-disrupting agent BNC105P in combination with gemcitabine-carboplatin in platinum-sensitive ovarian cancer patients in first or second relapse

A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients: Updated phase I results of the Disruptor-1 trial

Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC)

Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzobfuran (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties

Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors

Phase II trial of BNC105P as second-line chemotherapy for advanced malignant pleural mesothelioma (MPM): Australasian Lung Cancer Trials Group and NHMRC Clinical Trials Centre Collaboration

Suchergebnisse filtern